Cladribine therapy for systemic mastocytosis
- 15 December 2003
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 102 (13), 4270-4276
- https://doi.org/10.1182/blood-2003-05-1699
Abstract
Patients with systemic mastocytosis (SM) can suffer from disabling symptoms related to mast cell mediator release or mast cell infiltration, requiring mast cell eradication. In the present absence of any curative therapy, a recent case report describing the efficacy of cladribine showed promising results. In a pilot study, the efficacy of cladribine (0.10-0.13 mg/kg in a 2-hour infusion, days 1-5; repeated at 4-8 weeks until 6 cycles) was studied. Ten patients with SM with severe symptoms were treated. Four patients were classified as having indolent or smoldering mastocytosis, 3 as having aggressive systemic mastocytosis, and 3 as having SM with an accompanying hematologic malignancy. Nine patients received 6 courses, 1 patient stopped because of toxicodermia. All responded concerning signs, symptoms, and mast cell parameters (serum tryptase and urinary histamine metabolite excretion), although none achieved a complete remission. Prolonged follow-up is required, as response is ongoing in most cases. One patient relapsed within 11 months and showed a second response. Side effects were mainly related to bone marrow suppression. Single-agent cladribine is an effective and relatively safe treatment for severe systemic mastocytosis. The optimal dose and schedule need to be explored. (Blood. 2003;102:4270-4276)Keywords
This publication has 15 references indexed in Scilit:
- Mastocytosis: current concepts in diagnosis and treatmentAnnals of Hematology, 2002
- Treatment of Systemic Mast-Cell Disease with CladribineNew England Journal of Medicine, 2001
- TREATMENT OF SYSTEMIC MAST CELL DISORDERSHematology/Oncology Clinics of North America, 2000
- IFNα treatment in systemic mastocytosisAnnals of Hematology, 1999
- Serum tryptase measured with B12 and G5 antibody‐based immunoassays in mastocytosis patients and its relation to histamine turnoverBritish Journal of Dermatology, 1998
- Response of severe systemic mastocytosis to interferon alphaBritish Journal of Dermatology, 1998
- lnterferon-α in combination with corticosteroids improves systemic mast cell diseaseBritish Journal of Dermatology, 1995
- Classification and Diagnosis of Mastocytosis: Current StatusJournal of Investigative Dermatology, 1991
- Urinary excretion of histamine and some of its metabolites in man: Influence of the dietInflammation Research, 1984
- Determination of Nτ-methylhistamine in plasma and urine by isotope dilution mass fragmentographyClinica Chimica Acta; International Journal of Clinical Chemistry, 1981